Theorem Clinical Research

Drug Sponsors

Paratek Pharmaceuticals, Transcept Pharaceuticals to merge

Tuesday, July 1, 2014 02:51 PM

Transcept Pharmaceuticals of Point Richmond, Calif., and Boston-based Paratek Pharmaceuticals, a privately held biopharmaceutical company, have agreed to merge, with Paratek stockholders becoming the majority owners of Transcept. The operations of the two companies will be combined and the new entity will be named Paratek Pharmaceuticals.

More... »


Actavis completes Forest Laboratories acquisition

Tuesday, July 1, 2014 10:50 AM

Dublin-based Actavis has completed its acquisition of Forest Laboratories in a cash and equity transaction valued at approximately $28 billion. The combination creates a specialty pharmaceutical company with annual revenues of more than $15 billion anticipated for 2015.

More... »


India’s generics industry hires consultant to boost image

Monday, June 30, 2014 03:38 PM

Companies specializing in generic pharmaceuticals in India and the U.S. have retained India First Group to promote the benefits of affordable access to medicine as vital to improving healthcare worldwide. India First Group is a strategic advisory firm based in Washington, D.C. and New Delhi that assists U.S. companies pursuing business opportunities in India and supports Indian companies investing in the U.S.

More... »

Merz to acquire medical device company Ulthera

Friday, June 27, 2014 11:09 AM

Specialty healthcare company Merz will acquire Ulthera, a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications using its ultrasound platform technology. The merger is valued at up to $600 million in upfront cash and milestone payments.

More... »

Affymax to dissolve company

Thursday, June 26, 2014 01:52 PM

The board of directors of biopharmaceutical company Affymax has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all available cash to its stockholders.

More... »

IMS Health acquires Cegedim’s CRM and software developer unit

Thursday, June 26, 2014 12:45 PM

By Ronald Rosenberg
CenterWatch Staff Writer

IMS Health, which in the last year has been actively making acquisitions leading up to its April IPO, has announced its intention to acquire Paris-based Cegedim’s information solutions and customer relationship management (CRM) business for approximately $520 million in cash.

More... »

AbbVie outlines rationale for Shire offer

Wednesday, June 25, 2014 02:14 PM

Following Shire’s confirmed rejection of Abbvie’s offer on June 20, AbbVie has outlined its strategic rationale for, and background to, its proposal to the board of Shire of $34.74 in cash and 0.7988 ordinary shares of New AbbVie for each Shire share. The proposal represented an indicative value of $78.63 on May 29 (the latest practicable date before the proposal was made). While this cash and share mix is valued at $77.57 per share as of June 24, any firm offer made by AbbVie under Rule 2.7 of the Code will need to be equivalent to $78.63 per share.

More... »

Lundbeck completes acquisition of Chelsea Therapeutics

Wednesday, June 25, 2014 02:06 PM

Lundbeck has completed its acquisition of Chelsea Therapeutics International for $6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional $1.50 per share upon achievement of certain sales milestones.

More... »

InVivo Therapeutics realigns R&D strategy

Wednesday, June 25, 2014 01:54 PM

As a result of an in-depth review of the company's R&D portfolio, InVivo Therapeutics is realigning resources behind its novel Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells program for spinal cord injury (SCI).

More... »

Endo to acquire Dava Pharmaceuticals

Wednesday, June 25, 2014 01:50 PM

Endo International has reached a definitive agreement to acquire Dava Pharmaceuticals, a privately held company specializing in marketed, pre-launch and pipeline generic pharmaceuticals, for $575 million in cash, with additional cash consideration of up to $25 million contingent on the achievement of certain sales milestones. The acquisition enhances Endo's commercialization and development platform and is expected to be immediately accretive to Endo's 2014 adjusted earnings per share (EPS).

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 22

Roche/Genentech plans pilot trial to measure patientpreference for participating at home v. at study site

Bipartisan 21st Century Cures initiative prepares to draft legislation to accelerate biomedical R&D, lower cost

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs